EGFR and hemangiopericytoma: Sorafenib is amultikinase inhibitor that works by inhibiting epidermal growth factor receptor;VEGF receptors 1, 2, and 3; and platelet-derived growth factorreceptor-β.21Sorafenib is effective against hepatocellular carcinoma22-24 and softtissue sarcomas.25 This drug hasalso been tried for the treatment of patients with vascular tumors, includingangiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitaryfibrous tumor.26